Form 4: Moleculin Biotech CFO Reports Stock Transaction
Insider Transaction (Form 4)
Jonathan P. Foster, Chief Financial Officer of Moleculin Biotech, Inc., reported multiple transactions in common stock on November 4, 2026.
Summary
- Option exercise/conversion: acquired 41 Common Stock on November 4, 2026; holds 20,301 after (Direct).
- Tax/exercise-price withholding: disposed of 10 Common Stock at $8.46 ($85) on November 4, 2026; holds 20,291 after (Direct).
- Option exercise/conversion: disposed of 41 Restricted Stock Units on November 4, 2026; holds 70,854 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jonathan P. Foster — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-11-04 | Option exercise/conversion | Common Stock | 41 | — | — | 20,301 |
| 2026-11-04 | Tax/exercise-price withholding | Common Stock | 10 | $8 | $85 | 20,291 |
| 2026-11-04 | Option exercise/conversion | Restricted Stock Units | 41 | — | — | 70,854 |
Key Dates
| Date | Description |
|---|---|
| 2026-11-04 | Option exercise/conversion (41 shares) |
| 2026-11-04 | Tax/exercise-price withholding (10 shares) |
| 2026-11-04 | Option exercise/conversion (41 shares) |
Keywords
insider transaction, Form 4, MBRX, Moleculin Biotech, Inc., neutral, Jonathan P. Foster
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.